Patents by Inventor Brian W. Metcalf

Brian W. Metcalf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200140384
    Abstract: The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.
    Type: Application
    Filed: September 30, 2019
    Publication date: May 7, 2020
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Kobina N. Dufu, James Partridge, Hing Sham, Ming Yu
  • Publication number: 20200123176
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: August 20, 2019
    Publication date: April 23, 2020
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Publication number: 20200048280
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 18, 2019
    Publication date: February 13, 2020
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Patent number: 10435393
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: July 2, 2015
    Date of Patent: October 8, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Qing Xu, Zhe Li, Brian W. Metcalf
  • Patent number: 10428087
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: October 1, 2019
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Publication number: 20190202840
    Abstract: The present invention relates to salt forms of the phosphoinositide 3-kinase (PI3K) inhibitor (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one, pharmaceutical compositions comprising the same, and methods of using the salts and compositions for the treatment of PI3K-associated diseases such as cancer.
    Type: Application
    Filed: March 7, 2019
    Publication date: July 4, 2019
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Patent number: 10266551
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: April 23, 2019
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Publication number: 20190112287
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Application
    Filed: March 30, 2018
    Publication date: April 18, 2019
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Patent number: 10226459
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 12, 2019
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • Publication number: 20180362546
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Application
    Filed: April 23, 2018
    Publication date: December 20, 2018
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Publication number: 20180354929
    Abstract: Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation.
    Type: Application
    Filed: January 8, 2018
    Publication date: December 13, 2018
    Inventors: Brian W. Metcalf, Chihyuan Chuang
  • Patent number: 10125150
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: November 13, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Patent number: 10100040
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 16, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Zhe Li, Qing Xu, Brian W. Metcalf, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Publication number: 20180258105
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino)ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 13, 2018
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Patent number: 10017491
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 10, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Chihyuan Chuang
  • Publication number: 20180153882
    Abstract: The present invention provides a compound of Formula I or Formula II: enantiomer, diastereomer, prodrug, solvate, metabolite, or pharmaceutically acceptable salt thereof, wherein constituent variables are provided herein. The compounds of Formula I and II are modulators of metalloproteases and are useful in treating diseases associated with metalloprotease activity such as arthritis, cancer, cardiovascular disorders, skin disorders, inflammation and allergic conditions.
    Type: Application
    Filed: September 29, 2017
    Publication date: June 7, 2018
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Fenglei Zhang, Brian W. Metcalf
  • Patent number: 9988401
    Abstract: The present invention is related to crystalline forms of (S)-7-(1-(9H-purin-6-ylamino) ethyl)-6-(3-fluorophenyl)-3-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one which is a PI3K inhibitor useful in the treatment of cancer and other diseases.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: June 5, 2018
    Assignee: Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Hui-Yin Li
  • Patent number: 9981939
    Abstract: Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: May 29, 2018
    Assignee: Global Blood Therapeutics, Inc.
    Inventors: Brian W. Metcalf, Zhe Li, Qing Xu, Stephen L. Gwaltney, II, Jason R. Harris, Calvin W. Yee
  • Patent number: 9975907
    Abstract: The present invention provides pyrimidinones that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: May 22, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Yun-Long Li, Brian W. Metcalf, Andrew P. Combs
  • Patent number: 9957229
    Abstract: The present invention relates to inhibitors of 11-? hydroxyl steroid dehydrogenase type 1, antagonists of the mineralocorticoid receptor (MR), and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-? hydroxyl steroid dehydrogenase type 1 and/or diseases associated with aldosterone excess.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: May 1, 2018
    Assignees: Incyte Holdings Corporation, Incyte Corporation
    Inventors: Wenqing Yao, Jincong Zhuo, Meizhong Xu, Colin Zhang, Brian W. Metcalf, Chunhong He, Ding-Quan Qian